Life Biosciences says it has dosed the first human patient in an FDA-approved clinical trial testing an experimental therapy intended to reverse aspects of age-related cellular aging and vision loss. Both outlets report that the treatment is designed to address age-related blindness, with the company describing its approach as targeting underlying cellular changes rather than only managing symptoms. Gizmodo and Inc. both state that the initial dosing has occurred and that the trial is ongoing as the study moves forward from early testing in humans. The reporting frames the milestone as a significant early step in translating the company’s therapy concept into clinical evaluation under U.S. regulatory oversight. While details of the drug’s mechanism, dosing regimen, and trial endpoints are not provided in the excerpts, the shared information centers on the same key development: Life Biosciences administers its therapy to the first participant in an FDA-approved study aimed at restoring or improving sight and potentially influencing cellular aging processes.